CD19 and diffuse large B-cell lymphoma: This review aims to provide a comprehensive analysis of CD19 biology and its therapeutic relevance in DLBCL, with a specific focus on mechanisms of resistance, the impact of prior CD19-directed therapy, and the clinical feasibility of sequential targeting.